Insulet faces fraud suit as Omnipod recalls cut stock 12%

Insulet faces a securities fraud class action after two Omnipod recalls cut its stock 12% in 2026.

"Strong corporate governance isn't just good business, it's essential to maintaining investor trust," Brian J. Robbins, founding partner at Robbins LLP, said. "We believe fiduciaries should be accountable for their decisions and that shareholders deserve honesty, transparency, and fairness."

The complaint alleges Insulet failed to disclose material deficiencies in its manufacturing controls and procedures that created risks to the safety and reliability of certain Omnipod products. Insulet develops and sells insulin delivery systems for people with insulin-dependent diabetes through its Omnipod platform, which includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the Omnipod Eros Insulin Management System.

On March 12, 2026, the company initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through ongoing product monitoring. Shares fell $16.23, or 6.88%, to close at $219.84 on March 13. On May 26, Insulet announced a second correction covering Omnipod 5, Omnipod DASH, and Omnipod Eros Pods, citing a manufacturing issue that could result in insulin under-delivery. Shares dropped $7.79, or 5.07%, to $146.01 on May 27.

The manufacturing issue involved a tear in the internal tubing that delivers insulin, causing insulin to be released inside the Pod instead of being fully infused into the body as intended. The May 2026 correction expanded to all three Omnipod product lines, raising broader questions about Insulet's quality control as the company markets "medical grade quality at consumer electronic scale."

The case, Hu v. Insulet Corporation et al., No. 26-cv-13062, is pending in the U.S. District Court for the District of Massachusetts. The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Insulet securities between February 21, 2025 and May 26, 2026. Investors must move the court by August 31, 2026 to seek appointment as lead plaintiff. Bleichmar Fonti & Auld LLP and Rosen Law Firm have also announced class action notices related to the same allegations, and Grabar Law Office is investigating potential fiduciary duty claims.

The August 31 lead plaintiff deadline will determine which investor directs the litigation. A settlement or adverse judgment could add financial pressure to a company already facing scrutiny over product safety across its core insulin delivery platform, which serves a patient population that depends on reliable insulin delivery for daily diabetes management.

This article is for informational purposes only and does not constitute investment advice.